




I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Mail Stop RCE, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on December 23, 2003

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By _____


Amelia Weintraub

Attorney Docket No. 305J-900320US
Client Ref. No. SF2000-012-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ilse Bartke, et al.

Application No.: 09/854,142

Filed: May 10, 2001

For: NGF FOR THE PREVENTION OF
DEMYELINATION IN THE
NERVOUS SYSTEM

Examiner: Jon P. Weber

Art Unit: 1651

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the 1449 submitted on December 30, 2002, the first page of which has not yet been signed by the examiner. Copies of these references were previously submitted at the time of filing said IDS and are therefore not included in this mailing.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Paul Littlepage
Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

Application Number	09/854,142
Filing Date	May 10, 2001
First Named Inventor	Ilse Bartk
Group Art Unit	1651
Examiner Name	Jon P. Weber
Attorney Docket Number	305J-900320US
Date Submitted	December 23, 2003

O I P E
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

DEC 29 2003

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
01	Barde et al. (1980) Sensory neurons in culture: changing requirements for survival factors during embryonic development. Proc. Natl. Acad. Sci. USA. 77:1199-1203		
02	Bothwell (1995) Functional interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 18:223-253		
03	Cannella et al. (1998) The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 95:10100-10105		
04	Carter et al. (1997) Neurotrophins live or let die: does p75NTR decide? Neuron. 18: 187-190		
05	Charlton et al. (1995) The Th1/Th2 balance in autoimmunity. Curr. Opin. Immunol. 7:793-798		
06	De Simone et al. (1996) mRNA for NGF and p75 in the central nervous system of rats affected by experimental allergic encephalomyelitis. Neuropathol. Appl. Neurobiol. 22:54-59		
07	Dugan, et al. (1997) Rapid suppression of free radical formation by nerve growth factor involves the mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA. 94:4086-4091		
08	Fierz, et al. (1985) Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J. Immunol. 134:3785-3793		
09	Gadient et al. (1990) Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci. Lett. 117:335-340		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/854,142
Filing Date	May 10, 2001
First Named Inventor	Ils Bartke
Group Art Unit	1651
Examiner Name	Jon P. Weber
Attorney Docket Number	305J-900320US
Date Submitted	December 23, 2003

10	Genain et al. (1995) Antibody facilitation of multiple sclerosis-like lesions in a non human primate. <i>J. Clin. Invest.</i> 96:2966-2974
11	Genain et al. (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. <i>Nat. Med.</i> 5:170-175
12	Hohlfeld (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. <i>Brain.</i> 120:865-916 [Abstract].
13	Kossmann et al. (1996) Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. <i>Brain Res.</i> 713:143-152
14	Kramer et al. (1995) Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. <i>Nat. Med.</i> 1:1162-1166
15	Levi-Montalcini et al (1996) Nerve growth factor: from neurotropin to neurokine. <i>Trends Neurosci.</i> 19:514-520
16	Lewin et al. (1996) Physiology of the neurotrophins. <i>Annu. Rev. Neurosci.</i> 19:289-317
17	Lovett-Racke et al. (1998) Regulation of experimental allergic encephalomyelitis with insulin growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF/IGFBP3). <i>J. Clin. Invest.</i> 101: 1797-1804
18	Neumann, et al. (1998) Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. <i>Proc. Natl. Acad. Sci. USA.</i> 95:5779-5784
19	Raine (1997) Demyelinating diseases. In Davis R., Robertson., Eds. <i>Texbook of Neuropathology.</i> 3 rd ed. Baltimore, Williams & Wilkins, pp. 627-714.
20	Steinman, (2000) Multiple approaches to multiple sclerosis. <i>Nat. Med.</i> 6:15-16
21	Trapp, et al. (1998) Axonal transection in the lesions of multiple sclerosis. <i>N. Engl. J. Med.</i> 338:278-285
22	Urschel et al (1990) Schwann cell-neuronal interactions in the rat involve nerve growth factor. <i>J. Comp. Neurol.</i> 296:114-122
23	Villoslada et al. (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. <i>J. Exp. Med.</i> , 191(10): 1799-1806
24	Williams, et al. (1996) IL-10 production by adult human derived microglial cells. <i>Neurochem. Int.</i> 29:55-64

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY


(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

O I P
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

DEC 29 2003

(use as many sheets as necessary)



Complete if Known	
Application Number	09/854,142
Filing Date	May 10, 2001
First Named Inventor	Ilse Bartke
Group Art Unit	1651
Examiner Name	Jon P. W. ber
Attorney Docket Number	305J-900320US
Date Submitted	December 30, 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	AA	5,210,185		Della valle et al.	05-13-1993	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AB	WO	93/03140			02-18-1993		
	AC	WO	97/17087			05-15-1997		
	AD	EP	0 731 108			09-11-96		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AE	Unger et al., (1995) Poster: <u>25th Annual Meeting Society for Neuroscience, San Diego, California, USA</u> , November 11-16, 1995 (Presentation time: November 12, 1995); "Time course of regeneration in the adult pig brain following lysolecithin-induced demyelination."	
	AF	Miller, et al., (1996) <i>Brain Pathology</i> 6:331-34, "Central nervous system remyelination – clinical application of basic neuroscience principles".	
	AG	Koliatsos, et al., (1990) <i>The Journal of Neuroscience</i> 10(12):3801-3813, "Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey".	
	AH	McMorris and McKinnon, (1996) <i>Brain Pathology</i> , 6:313-329 "Regulation of oligo dendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease."	
	AI	Kramer, et al., (1995) <i>Nature Medicine</i> , vol. 1, No. 11:1162-1166, "Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis."	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/854,142
		Filing Date	May 10, 2001
		First Named Inventor	Ils Bartk
		Group Art Unit	1651
		Examiner Name	Jon P. W. ber
		Attorney Docket Number	305J-900320US
		Date Submitted	December 30, 2002

AJ	Althaus, et al., (1992) <i>Neuroscience Letters</i> 135:219-223, "Nerve growth factor induces proliferation and enhances fiber regeneration in oligodendrocytes isolated from adult pig brain."	
AK	Gage, et al., (1988) <i>The Journal of Comparative Neurology</i> , 269:147-155, "Morphological respnse of axotomized septal neurons to nerve growth factor."	
AL	Hefti et al, (1984) <i>Brain Research</i> 293:305-311, "Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions."	
AM	Hefti, (1986) <i>The Journal of Neuroscience</i> , vol. 6, No. 8, p. 2155-2162, "Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections."	
AN	Crain and Patterson, (1974) <i>Brain Research</i> , 79:145-152, "Enhanced afferent synaptic functions in fetal mouse spinal cord-sensory ganglion explants following NGF-induced ganglion hypertrophy."	
AO	Chun and Patterson, (1977) <i>The Journal of Cell Biology</i> , vol. 75, pp. 596-704, "Role of nerve growth factor in the development of rat sympathetic neurons in vitro – I. Survival, growth and differentiation of catecholamine production."	
AP	Chun and Patterson, (1977) <i>The Journal of Cell Biology</i> , vol. 75, pp. 704-711, "Role of nerve growth factor in the development of rat sympathetic neurons in vitro – II. Developmental studies."	
AQ	Levi-Montalcini and Angeletti, (1963) <i>Developmental Biology</i> , 7:653-659, "Essential role of the nerve growth factor in the survival and maintenance of dissociated sensory and sympathetic embryonic nerve cells in vitro."	
AR	Massacesi, et al., (1995) <i>Annals of Neurology</i> , vol. 37, No. 4, pp. 519-530, "Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for muliple sclerosis."	
AS	Althaus et al., (1990) <i>Cellular and Molecular Biology of Myelination</i> , Monastery Ohrbeck, FRG, August 28-September 2, 1989; NATO ASI Series, Vol. H43, edited by G. Jeserich et al., Springer Verlag Berlin Heidelberg 1990; pp. 247-253 "Protein kinases A and C are involved in oligodendroglial process formation."	
AT	Diaz-Villoslada et al., (1996) Abstract: American Neurology Association Meeting, October 13-16, 1996, Miami, FL, USA, "Recombinant human nerve growth factor prevents autoimmune demyelination in marmosets."	
AU	Engel et al., (1994) <i>NeuroReport</i> 5:397-400, "NGF increases $[Ca^{2+}]_i$ in regenerating mature oligodendrolial cells."	
AV	Althaus and Siepl, (1997) <i>Cell Tissue Res.</i> 287:135-141, "Oligodendrocytes isolated from adult pig brain synthesise and release prostaglandins."	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/854,142
		Filing Date	May 10, 2001
		First Named Inventor	Ilse Bartk
		Group Art Unit	1651
		Examiner Name	Jon P. Weber
		Attorney Docket Number	305J-900320US
		Date Submitted	December 30, 2002

	AW	Diaz-Cintra, et al., (1995) <i>Cell Transplantation</i> , Vol. 4, No. 5, pp. 505-513, "Morphometric study of fetal brain transplants in the insular cortex and NGF effects on neuronal and glial development."	
	AX	Schmidt-Schulz and Althaus, (1994) <i>Journal of Neurochemistry</i> , 62:1478-1585, "Monogalactosyl diglyceride, a marker for myelination. Activates oligodendroglial protein kinase C."	
	AY	Cohen, et al., (1996) <i>The Journal of Neuroscience</i> , Vol. 16, No. 20, pp. 6433-6442, "Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes."	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.